Cadwalader Represents Credit Suisse in Connection With AcelRx Pharmaceuticals’ $65 Million Monetization of Expected Royalty Stream From Zalviso™

Sep 21, 2015

Contact(s)

Kimberly Brooks
New York
+1 212 504 5652
kimberly.brooks@cwt.com

Cadwalader  is pleased to announce it represented Credit Suisse in a transaction for which Credit Suisse was the sole structuring and financial advisor to AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) in the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil sublingual tablet system) in the European Union by its commercial partner Grunenthal GmbH. AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that gross proceeds from the sale are $65 million.

The Cadwalader team included Christopher Cox, Corporate; Ira Schacter and Steve Lenkowsky, Capital Markets; Dorothy Auth, Intellectual Property; and David Miller, Tax.  

CadwaladerSpotlight

April 19: Trading Risk's London ILS Conference 2018

Robert Cannon will discuss the U.K.’s new insurance-linked securities framework.

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.